Spleen volume reduction and transfusion independence with momelotinib vs ruxolitinib and associated overall survival with momelotinib in JAK inhibitor–naive patients with myelofibrosis and anemia: subgroup analyses of SIMPLIFY-1
Clinical Lymphoma Myeloma and Leukemia · 2026
DOI: 10.1016/j.clml.2026.02.004 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2026. Verfasst von Francesca Palandri und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical and Surgical Sciences, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy. Electronic address: francesca.paland…. Hauptthemen laut MEDLINE: Anemia, Benzamides, Nitriles, Primary Myelofibrosis. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
INTRODUCTION: Improvements in splenomegaly, anemia, and overall survival (OS) are key considerations in the management of patients with myelofibrosis. In the phase III SIMPLIFY-1 trial (NCT01969838), momelotinib was noninferior to ruxolitinib for spleen volume reduction ≥ 35% (SVR35) and nominally superior for transfusion independence (TI) at week 24 in Janus kinase (JAK) inhibitor-naive patients. However, the relative impact of these endpoints on OS in anemic patients has not been described. MATERIALS AND METHODS: The present post hoc analysis evaluated week 24 SVR35, TI, and dual responses (SVR35 + TI) in patients with baseline hemoglobin < 10 g/dL. RESULTS: SVR35 rates were similar overall with momelotinib versus ruxolitinib (27/86 [31%] vs. 31/94 [33%]), but higher with momelotinib in the baseline platelets < 200 × 109/L subgroup (19/49 [39%] vs. 8/47 [17%]) and with ruxolitinib in the baseline platelets ≥ 200 × 109/L subgroup (8/37 [22%] vs. 23/47 [49%]). Week 24 SVR35 + TI was also more common with momelotinib (23/86 [27%]) than with ruxolitinib (7/94 [7%]). Subsequent OS analysis focused on the momelotinib arm only, as the crossover trial design precluded analysis of long-term OS with ruxolitinib. OS was longer in patients who were transfusion independent and/or achieved SVR35 at week 24 versus those who met neither endpoint (TI alone: n = 17, hazard ratio [HR], 0.25 [95% CI, 0.09-0.70]; SVR35 + TI: n = 23, HR, 0.40 [95% CI, 0.18-0.87]). CONCLUSION: These results highlight that both spleen- and anemia-related benefits of momelotinib correlate with improved OS, supporting prioritization of TI in anemic patients for optimal long-term outcomes, and suggest that momelotinib may be the preferred JAK inhibitor in anemic patients with platelets < 200 × 109/L.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical and Surgical Sciences, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy. Electronic address: francesca.palandri@unibo.it.
- Department of Hematology, Radboud University Medical Center, Nijmegen, the Netherlands.
- Department of Hematology, Institut Paoli-Calmettes, Marseille, France.
- Department of Hematology and Oncology, University Medical Center Schleswig-Holstein (UKSH) and University Cancer Center Schleswig-Holstein (UCCSH), Campus Lübeck, Lübeck, Germany.
- Department of Hematology and Oncology, University Hospital Mannheim, Heidelberg University, Mannheim, Germany.
- Department of Hematology, Hospital Clìnico de Valencia-INCLIVA, University of Medicine, Valencia, Spain.
Zitieren
APA
Palandri, F., Schaap, N. P. M., Rey, J., von Bubnoff, N., Reiter, A., Hernandez-Boluda, J. C., Devos, T., Nilsson, L., Psaila, B., McLornan, D. P., Strouse, B., Zhang, S., Patel, B., Lim, J., Patnaik, D., & Oh, S. T. (2026). Spleen volume reduction and transfusion independence with momelotinib vs ruxolitinib and associated overall survival with momelotinib in JAK inhibitor–naive patients with myelofibrosis and anemia: subgroup analyses of SIMPLIFY-1. Clinical Lymphoma Myeloma and Leukemia. https://doi.org/10.1016/j.clml.2026.02.004
Vancouver
Palandri F, Schaap NPM, Rey J, von Bubnoff N, Reiter A, Hernandez-Boluda JC, et al. Spleen volume reduction and transfusion independence with momelotinib vs ruxolitinib and associated overall survival with momelotinib in JAK inhibitor–naive patients with myelofibrosis and anemia: subgroup analyses of SIMPLIFY-1. Clinical Lymphoma Myeloma and Leukemia. 2026. doi:10.1016/j.clml.2026.02.004
BibTeX
@article{Palandri2026,
author = {Palandri, Francesca and Schaap, Nicolaas P M and Rey, Jerome and von Bubnoff, Nikolas and Reiter, Andreas and Hernandez-Boluda, Juan Carlos and Devos, Timothy and Nilsson, Lars and Psaila, Bethan and McLornan, Donal P and Strouse, Bryan and Zhang, Shiyuan and Patel, Bharat and Lim, Jessica and Patnaik, Dwaipayan and Oh, Stephen T},
title = {Spleen volume reduction and transfusion independence with momelotinib vs ruxolitinib and associated overall survival with momelotinib in JAK inhibitor–naive patients with myelofibrosis and anemia: subgroup analyses of SIMPLIFY-1},
journal = {Clinical Lymphoma Myeloma and Leukemia},
year = {2026},
doi = {10.1016/j.clml.2026.02.004}
}
EUVIMED